Weight gain in children with hypertonia of cerebral origin receiving intrathecal baclofen therapy.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 17084127.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To identify the pattern of weight change in children receiving intrathecal baclofen (ITB) therapy. A retrospective medical chart review was conducted to identify weight status before and after ITB pump implantation. Tertiary care children's hospital and academic medical center. All children and adolescents with hypertonia of cerebral origin who were younger than 19 years of age at the time of pump placement and followed in our pediatric baclofen pump program. Not applicable. A linear mixed model was used to examine the rate of change in weight (weight-gain velocity) before and after surgery. Weight change was adjusted for age, sex, functional level determined by the Gross Motor Functional Classification System, tube feeding, dystonia, and other comorbidities. The average weight-gain velocity was 2.32 kg/y presurgery and 2.93 kg/y postsurgery, adjusted for potential confounders. The 0.61 kg/y increase in weight-gain velocity attained statistical significance (P = .028). Although excessive weight gain is not a common problem in children with cerebral origin spasticity, increased weight-gain velocity is prevalent in children receiving ITB therapy. Health care providers may anticipate a welcome weight gain in the underweight child. This consequence should be considered when managing children receiving ITB therapy, and health care providers must appropriately intervene to prevent excessive weight gain. Further studies exploring the reasons for the increased weight-gain velocity are warranted.
Medical subject headings
- Baclofen
- Muscle Hypertonia
- Muscle Relaxants, Central
- Weight Gain